Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Severity-Related Increase and Cognitive Correlates of Serum VEGF Levels in Alzheimer's Disease ApoE4 Carriers.

Alvarez XA, Alvarez I, Aleixandre M, Linares C, Muresanu D, Winter S, Moessler H.

J Alzheimers Dis. 2018;63(3):1003-1013. doi: 10.3233/JAD-160477.

PMID:
29710700
2.

Correction for Sugimoto et al., "Critical Role for Monocytes/Macrophages in Rapid Progression to AIDS in Pediatric Simian Immunodeficiency Virus-Infected Rhesus Macaques".

Sugimoto C, Merino KM, Hasegawa A, Wang X, Alvarez XA, Wakao H, Mori K, Kim WK, Veazey RS, Didier ES, Kuroda MJ.

J Virol. 2017 Oct 27;91(22). pii: e01346-17. doi: 10.1128/JVI.01346-17. Print 2017 Nov 15. No abstract available.

3.

Critical Role for Monocytes/Macrophages in Rapid Progression to AIDS in Pediatric Simian Immunodeficiency Virus-Infected Rhesus Macaques.

Sugimoto C, Merino KM, Hasegawa A, Wang X, Alvarez XA, Wakao H, Mori K, Kim WK, Veazey RS, Didier ES, Kuroda MJ.

J Virol. 2017 Aug 10;91(17). pii: e00379-17. doi: 10.1128/JVI.00379-17. Print 2017 Sep 1. Erratum in: J Virol. 2017 Oct 27;91(22):.

4.

Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases.

Alvarez XA, Alvarez I, Iglesias O, Crespo I, Figueroa J, Aleixandre M, Linares C, Granizo E, Garcia-Fantini M, Marey J, Masliah E, Winter S, Muresanu D, Moessler H.

Int J Neuropsychopharmacol. 2016 Apr 7. pii: pyw024. doi: 10.1093/ijnp/pyw024. [Epub ahead of print]

5.

Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease.

Rockenstein E, Ubhi K, Pham E, Michael S, Doppler E, Novak P, Inglis C, Mante M, Adame A, Alvarez XA, Moessler H, Masliah E.

J Neurosci Res. 2011 Nov;89(11):1812-21. doi: 10.1002/jnr.22712. Epub 2011 Jul 25.

6.

Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.

Alvarez XA, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M, Linares C, Granizo E, García-Fantini M, Baurecht W, Doppler E, Moessler H.

Curr Alzheimer Res. 2011 Aug;8(5):583-91.

PMID:
21679156
7.

Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study.

Muresanu DF, Alvarez XA, Moessler H, Novak PH, Stan A, Buzoianu A, Bajenaru O, Popescu BO.

J Neurol Sci. 2010 Dec 15;299(1-2):179-83. doi: 10.1016/j.jns.2010.08.040.

PMID:
20923712
8.

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.

Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, Doppler E, Moessler H.

Eur J Neurol. 2011 Jan;18(1):59-68. doi: 10.1111/j.1468-1331.2010.03092.x.

PMID:
20500802
9.

Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin.

Alvarez XA, Sampedro C, Cacabelos R, Linares C, Aleixandre M, García-Fantini M, Moessler H.

Int J Neuropsychopharmacol. 2009 Aug;12(7):867-72. doi: 10.1017/S1461145709990101. Epub 2009 Jun 17.

PMID:
19531281
10.

Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury.

Alvarez XA, Sampedro C, Figueroa J, Tellado I, González A, García-Fantini M, Cacabelos R, Muresanu D, Moessler H.

J Neural Transm (Vienna). 2008 May;115(5):683-92. doi: 10.1007/s00702-008-0024-9. Epub 2008 Feb 14.

PMID:
18273537
11.

A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration.

Muresanu DF, Alvarez XA, Moessler H, Buia M, Stan A, Pintea D, Moldovan F, Popescu BO.

J Neurol Sci. 2008 Apr 15;267(1-2):112-9. Epub 2007 Nov 28.

PMID:
18048059
12.

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H.

Eur J Neurol. 2006 Jan;13(1):43-54.

PMID:
16420392
13.

Neuropeptide dietary supplement N-PEP-12 enhances cognitive function and activates brain bioelectrical activity in healthy elderly subjects.

Alvarez XA, Corzo L, Laredo M, Sampedro C, Cacabelos R, Windisch M, Moessler H, Crook TH.

Methods Find Exp Clin Pharmacol. 2005 Sep;27(7):483-7.

PMID:
16258593
14.

Effects of N-PEP-12 on memory among older adults.

Crook TH, Ferris SH, Alvarez XA, Laredo M, Moessler H.

Int Clin Psychopharmacol. 2005 Mar;20(2):97-100.

PMID:
15729085
15.

Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study.

Alvarez XA, Sampedro C, Pérez P, Laredo M, Couceiro V, Hernández A, Figueroa J, Varela M, Arias D, Corzo L, Zas R, Lombardi V, Fernández-Novoa L, Pichel V, Cacabelos R, Windisch M, Aleixandre M, Moessler H.

Int Clin Psychopharmacol. 2003 Sep;18(5):271-8.

PMID:
12920387
16.

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).

Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G.

Brain Res. 2002 Dec 20;958(1):210-21.

PMID:
12468047
18.

Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease.

Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C.

Prog Neuropsychopharmacol Biol Psychiatry. 2001 Oct;25(7):1341-57. Review.

PMID:
11513350
19.

Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.

Alvarez XA, Pichel V, Pérez P, Laredo M, Corzo D, Zas R, Fernández-Novoa L, Sempere JM, Díaz J, Cacabelos R.

Methods Find Exp Clin Pharmacol. 2000 Sep;22(7):585-94.

PMID:
11196347
20.

Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects.

Alvarez XA, Lombardi VR, Corzo L, Pérez P, Pichel V, Laredo M, Hernández A, Freixeiro F, Sampedro C, Lorenzo R, Alcaraz M, Windisch M, Cacabelos R.

J Neural Transm Suppl. 2000;59:315-28.

PMID:
10961443
21.

Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection.

Alvarez XA, Lombardi VR, Fernández-Novoa L, García M, Sampedro C, Cagiao A, Cacabelos R, Windisch M.

J Neural Transm Suppl. 2000;59:281-92.

PMID:
10961440
22.

Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.

Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1999 Nov;21(9):633-44.

PMID:
10669911
23.

Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats.

Alvarez XA, Sampedro C, Lozano R, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1999 Oct;21(8):535-40.

PMID:
10599052
24.

Intrahippocampal injections of the beta-amyloid 1-28 fragment induces behavioral deficits in rats.

Alvarez XA, Miguel-Hidalgo JJ, Fernández-Novoa L, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1997 Sep;19(7):471-9.

PMID:
9413830
25.

APOE epsilon 4 allele frequency in Alzheimer's disease and vascular dementia in the Spanish population.

Beyer K, Lao JI, Fernández-Novoa L, Alvarez XA, Sellers MA, Cacabelos R.

Ann N Y Acad Sci. 1997 Sep 26;826:452-5. No abstract available.

PMID:
9329722
26.

Global Deterioration Scale-related brain hemodynamics and histamine levels in Alzheimer's disease and vascular dementia.

Fernandez-Novoa L, Corzo L, Zas R, Alvarez XA, Cacabelos R.

Ann N Y Acad Sci. 1997 Sep 26;826:396-400. No abstract available.

PMID:
9329711
27.

Cerebrovascular changes associated with interleukin-1 beta (IL-1 beta) and histamine (HA) levels in Alzheimer's disease.

Alvarez XA, Fernández-Novoa L, Caamaño J, Corzo L, Zas R, Beyer K, Lao JI, Cacabelos R.

Ann N Y Acad Sci. 1997 Sep 26;826:375-8. No abstract available.

PMID:
9329706
28.

Anapsos reverses interleukin-1 beta overexpression and behavioral deficits in nbM-lesioned rats.

Alvarez XA, Franco-Maside A, Zas R, Sempere JM, Díaz J, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1997 Jun;19(5):299-309.

PMID:
9379778
29.

Citicoline improves memory performance in elderly subjects.

Alvarez XA, Laredo M, Corzo D, Fernández-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1997 Apr;19(3):201-10.

PMID:
9203170
30.

Effects of anapsos on the activity of the enzyme Cu-Zn-superoxide dismutase in an animal model of neuronal degeneration.

Fernández-Novoa L, Alvarez XA, Sempere JM, Miguel-Hidalgo JJ, Díaz J, Franco-Maside A, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1997 Mar;19(2):99-106.

PMID:
9151285
31.

A general method for DNA polymorphism identification in genetic assessment and molecular diagnosis.

Beyer K, Lao JI, Alvarez XA, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1997 Mar;19(2):87-91.

PMID:
9151283
32.

Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease.

Alvarez XA, Franco A, Fernández-Novoa L, Cacabelos R.

Mol Chem Neuropathol. 1996 Oct-Dec;29(2-3):237-52.

PMID:
8971699
33.

Effects of S-9977-2 on histamine levels in rats.

Fernández-Novoa L, Alvarez XA, Détolle-Sarbach S, Guez D, Zas R, Polo E, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1996 Apr;18(3):197-203.

PMID:
8738071
34.

Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors.

Cacabelos R, Caamaño J, Gómez MJ, Fernández-Novoa L, Franco-Maside A, Alvarez XA.

Ann N Y Acad Sci. 1996 Jan 17;777:399-403.

PMID:
8624120
35.

Brain electrical activity in neurogerontology and psychogeriatric disorders.

Franco-Maside A, Vinagre D, Caamaño J, Alvarez XA, Fernández-Novoa L, Novo B, Zas R, Gómez MJ, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1995 Apr;17(3):207-24. Review. No abstract available.

PMID:
8531511
36.

Transcranial Doppler ultrasonography in neurogeriatric disorders.

Caamaño J, Gómez MJ, Vinagre D, Franco A, Fernández-Novoa L, Alvarez XA, Novo B, Zas R, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1995 Mar;17(2):135-48. Review. No abstract available.

PMID:
7674701
37.

Effects of histamine and alpha-fluoromethylhistidine on brain tumor necrosis factor levels in rats.

Fernández-Novoa L, Franco-Maside A, Alvarez XA, Cacabelos R.

Inflamm Res. 1995 Jan;44(1):55-7.

PMID:
7664030
38.

Effects of neurotoxic lesions in the posterior hypothalamic region on psychomotor activity and learning.

Alvarez XA, Franco A, Fernández-Novoa L, Cacabelos R.

Agents Actions. 1994 Nov;43(1-2):21-3.

PMID:
7741035
39.

Effects of neurotoxic lesions in histaminergic neurons on brain tumor necrosis factor levels.

Alvarez XA, Franco A, Fernández-Novoa L, Cacabelos R.

Agents Actions. 1994 Jun;41 Spec No:C70-2.

PMID:
7976809
40.

CDP-choline-induced blood histamine changes in Alzheimer's disease.

Fernández-Novoa L, Alvarez XA, Franco-Maside A, Caamaño J, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1994 May;16(4):279-84.

PMID:
8051988
41.

Brain interleukin-1 beta in Alzheimer's disease and vascular dementia.

Cacabelos R, Alvarez XA, Fernández-Novoa L, Franco A, Mangues R, Pellicer A, Nishimura T.

Methods Find Exp Clin Pharmacol. 1994 Mar;16(2):141-51.

PMID:
8007743
42.

Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia.

Cacabelos R, Alvarez XA, Franco-Maside A, Fernández-Novoa L, Caamaño J.

Methods Find Exp Clin Pharmacol. 1994 Jan-Feb;16(1):29-35.

PMID:
8164471
43.

Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia.

Cacabelos R, Alvarez XA, Franco-Maside A, Fernández-Novoa L, Caamaño J.

Ann N Y Acad Sci. 1993 Sep 24;695:321-3.

PMID:
8239305
44.

Influence of growth hormone (GH) and GH-releasing factor on locomotor activity in rats.

Alvarez XA, Cacabelos R.

Peptides. 1993 Jul-Aug;14(4):707-12.

PMID:
8234013
45.

Serum histamine in Alzheimer's disease and multi-infarct dementia.

Cacabelos R, Fernández-Novoa L, Pérez-Trullén JM, Franco-Maside A, Alvarez XA.

Methods Find Exp Clin Pharmacol. 1992 Nov;14(9):711-5.

PMID:
1294859
46.

Interleukin-1 in Alzheimer's disease and multi-infarct dementia: neuropsychological correlations.

Cacabelos R, Franco-Maside A, Alvarez XA.

Methods Find Exp Clin Pharmacol. 1991 Dec;13(10):703-8.

PMID:
1770834
47.

Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders.

Cacabelos R, Barquero M, García P, Alvarez XA, Varela de Seijas E.

Methods Find Exp Clin Pharmacol. 1991 Sep;13(7):455-8.

PMID:
1784142
48.
49.

Effects of GRF (1-29) NH2 on short-term memory: neuroendocrine and neuropsychological assessment in healthy young subjects.

Alvarez XA, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1990 Sep;12(7):493-9.

PMID:
2087150
50.

Antagonistic effects of growth hormone-releasing factor (GRF) and somatostatin on locomotor activity: GRF-induced hyperkinetic syndrome.

Cacabelos R, Niigawa H, Alvarez XA, Muñoz MD, Nishimura T, Rubia FJ.

Methods Find Exp Clin Pharmacol. 1990 Jul-Aug;12(6):425-34.

PMID:
1982332

Supplemental Content

Loading ...
Support Center